Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its price objective hoisted by stock analysts at Mizuho from $105.00 to $116.00 in a report issued on Wednesday, Marketbeat reports. The firm presently has a “neutral” rating on the stock. Mizuho’s target price indicates a potential downside of 6.53% from the company’s previous close. Other equities research […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 3,580,000 shares, a decrease of 17.1% from the May 15th total of 4,320,000 shares. Currently, 3.8% of the shares of the stock are short sold. Based on […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) has earned a consensus rating of “Hold” from the twenty-one research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and ten have given a buy rating to the company. The […]
Brokerages predict that Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) will report $337.91 million in sales for the current fiscal quarter, according to Zacks. Eleven analysts have issued estimates for Neurocrine Biosciences’ earnings. The highest sales estimate is $362.70 million and the lowest is $313.00 million. Neurocrine Biosciences posted sales of $288.90 million in the […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) – Stock analysts at Oppenheimer reduced their FY2026 earnings per share estimates for shares of Neurocrine Biosciences in a report issued on Wednesday, May 25th. Oppenheimer analyst J. Olson now anticipates that the company will post earnings of $10.56 per share for the year, down from their previous […]